Consensus NovoCure Limited

Stocks

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-09-18 EDT			5-day change	1st Jan Change
16.69 ^USD	-0.18%		+7.61%	+29.08%

09-09	Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026	CI
09-04	US companies face rise in cyber attacks	RE

Evolution of the Average Target: NovoCure Limited

Evolution of the Target Price: NovoCure Limited

Changes in Analyst Recommendations: NovoCure Limited

11b135f7e9d4a5.zct-Pd3wJJdwP9gPZpYZytt2W7bPXsCGFrv9jkoEVdQ.i6EqTY6TZdYIWrd_Pv8p86sVDd-6OIzvbMzM1AxVAKeDujNR8JR93iBUnQ~974db7981f05a63b2e72f99be89f2b53

Analysts' recommendations: NovoCure Limited

07-24	Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating	MT
25-07-25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
25-07-25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
25-07-24	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT
25-07-08	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
24-12-02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
24-12-02	Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	MT
24-12-02	Evercore ISI Upgrades NovoCure to Outperform	MT
24-10-16	HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	MT
24-06-04	Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	MT
24-04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT
24-04-03	Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	MT
24-02-23	Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	MT
23-10-26	Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	MT
23-08-29	Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	MT
23-08-28	HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	MT
23-08-28	Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	MT
23-08-08	Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	MT
23-08-04	SVB Securities Initiates NovoCure at Outperform With $51 Price Target	MT
23-07-31	Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
23-06-07	Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT

More recommendations

Medical Equipment

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
NOVOCURE LIMITED			+62.34%
PENUMBRA, INC.			+13.47%
GETINGE AB			+3.73%
MINIMED GROUP, INC.			+11.42%
ASAHI INTECC CO., LTD.			+36.33%
APT MEDICAL INC.			+36.64%
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.			+39.16%
IMPLANTICA AG	-	-	+53.99%
NAKANISHI INC.			+17.07%
CHEMOMETEC A/S			+21.76%
Average			+29.59%
Weighted average by Cap.			+23.14%